Is NCT06815432 recruiting in Houston, TX?

Yes, NCT06815432 is currently recruiting participants at its Houston, TX location. This glioblastoma multiforme of brain clinical trial is actively enrolling qualified participants.

How do I join the glioblastoma multiforme of brain clinical trial in Houston?

To join this clinical trial in Houston, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Houston clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Glioblastoma Multiforme of Brain Clinical Trial in Houston, TX

About This Glioblastoma Multiforme of Brain Study in Houston

The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T-cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including cells infected with viruses and tumor cells. Both antibodies and T cells have been used to treat participants with cancers. They have shown promise, but have not been strong enough to cure most participants. The study team has found from previous research that we can put a new gene (a tiny part of what makes-up DNA and carries the participants traits) into T cells that will make them recognize cancer cells and kill them. In the lab, the study team has made several genes called a chimeric antigen receptor (CAR), from an antibody called GC33. The antibody GC33 recognizes a protein found on the participants brain tumor. This CAR is called GPC3-CAR. To make this CAR more effective, the study has also added a gene that includes IL15. IL15 is a protein that helps CAR T cells grow better and stay in the blood longer so that they may kill tumors better. The mixture of GPC3-CAR and IL15 killed tumor cells better in the laboratory when compared with CAR T cells that did not have IL15. This study will test T cells with the IL15 GPC3-CAR (GO-CART T cells) in participants with GPC3-positive brain tumors. T cells made to carry a gene called iCasp9 can be killed when they encounter a specific drug called AP1903. The study team will insert the iCasp9 and IL15 together into the T cells using a virus that has been made for this study. The drug (AP1903) is an experimental drug that has been tested in humans with no bad side-effects. The study team will use this drug to kill the T cells if necessary due to side effects. This study will test T cells genetically engineered with a GPC3-CAR and IL15 (GO-CART T cells) in participants with GPC3-positive brain tumors. The GO-CART T cells are an investigational product not approved by the Food and Drug Administration.

Sponsor: Baylor College of Medicine

Who Can Participate

Inclusion Criteria

Diagnosis of GPC3-positive recurrent glioblastoma with previous resection planned for repeat resection.

Age ≥18 years

Karnofsky score ≥60%

Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent

GPC3 expression (as determined by immunohistochemistry) with an extent score of ≥ Grade 2 (\>25% positive tumor cells) and an intensity score of ≥ 2 (scale 0-4). Procurement

Exclusion Criteria

History of hypersensitivity reactions to murine protein-containing products OR presence of human anti-mouse antibody (HAMA) prior to enrollment (only patients who have received prior therapy with murine antibodies).

History of organ transplantation

Known HIV positivity

Active bacterial, fungal or viral infection (except Hepatitis B or Hepatitis C virus infections).

Exhibits other risk factors of which administration of investigational agent is deemed not in the patient's best interest, in the opinion of the investigator Treatment Inclusion Criteria:

Age ≥ 18 years

Diagnosis of recurrent glioblastoma with previous resection

Karnofsky score ≥ 60%-

Stable neurologic exam for 7 days prior to enrollment

Stable or decreasing dose of steroids over past 7 days prior to surgery and administration of therapy (max allowable dose is 0.1mg/kg dexamethasone or equivalent per day)

Adequate organ function:

Creatinine clearance as estimated by Cockcroft Gault or Schwartz ≥ 60 ml/min

total bilirubin \< 3 times ULN for age

absolute neutrophil count \> 500/μl

platelet count \> 100,000/μl (can be transfused but must be achieved prior to enrollment)

Hgb ≥ 7.0 g/dl (can be transfused)

Pulse oximetry \>90% on room air

Recovered from acute toxic effects of all prior chemotherapy and investigational agents before entering this study

Sexually active patients must be willing to utilize one of the more effective birth control methods for 3 months after the T-cell infusion.

Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent. Treatment Exclusion Criteria:

Pregnancy or lactation

Uncontrolled infection

Known HIV positivity

Active bacterial, fungal or viral infection

History of organ transplantation

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Houston?

Yes, this clinical trial (NCT06815432) has an active research site in Houston, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Glioblastoma Multiforme of Brain Treatment Options in Houston, TX

If you're searching for glioblastoma multiforme of brain treatment options in Houston, TX, this clinical trial (NCT06815432) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Houston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced glioblastoma multiforme of brain specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all glioblastoma multiforme of brain clinical trials near you to find additional studies recruiting in your area.

Glioblastoma Multiforme of Brain Clinical Trial in Houston, TX

Expert Care in Houston

IRB Approved

No-Cost Care

Apply for This Houston Location

Why Participate?

Simple Process